Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
about
Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL ProteaseChallenges and advances in the assessment of the disposition of antibody-drug conjugatesPlanar microdevices enhance transport of large molecular weight molecules across retinal pigment epithelial cells.Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugsEmerging mass spectrometry-based approaches to probe protein-receptor interactions: focus on overcoming physiological barriersPitfalls in protein quantitation using acid-catalyzed O18 labeling: hydrolysis-driven deamidation.Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeuticsPharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.ADME of biologics-what have we learned from small molecules?Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis.Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics.Recent Advances in the Discovery of Norovirus Therapeutics.Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Receptor-mediated endocytosis and brain delivery of therapeutic biologics.ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools.Native chemical ligation: a boon to peptide chemistry.Strategic approaches to optimizing peptide ADME propertiesClinical pharmacology of albiglutide, a GLP-1 receptor agonist.Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research.Overview on biotherapeutic proteins: impact on bioanalysis.An efficient liquid chromatography-high resolution mass spectrometry approach for the optimization of the metabolic stability of therapeutic peptides.Quantitation and pharmacokinetic modeling of therapeutic antibody quality attributes in human studies.Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers.Evaluation of Gallium as a Tracer of Exogenous Hemoglobin-Haptoglobin Complexes for Targeted Drug Delivery Applications.Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers.Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis.Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.Pharmacokinetics of teduglutide in subjects with renal impairment.Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.Pharmacokinetics of single and repeat doses of icatibant.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.In Silico ADME/Tox Predictions
P2860
Q27703748-3B2100A5-33F9-486E-91DD-DAD53EA91847Q28085074-DE26BBD6-FB4E-49B7-8913-1FAF3B9819C9Q33849404-AE403A94-A17A-4F56-9272-BC583A86D51EQ34011214-72D17C58-D363-48C8-9C64-EB2B4C236467Q34691652-3656F4C1-C6F7-42B0-9A36-0FBC2D777B97Q35214327-76D8FD03-BFA9-44DC-A43A-0FA428EE6DFDQ35223810-182EA336-A087-4EE3-8DEF-E2BD54F60582Q35929084-50E2D65B-C861-4F20-AEF6-18C995010D75Q36065589-3537C7D7-FBDB-4ECA-B6A9-7AEB2ECD8AFBQ36125978-0B18A71E-2B48-430A-AC47-29123AF59EF1Q36331497-C3BF17C0-E6D7-4AB4-8D2C-8FF66BAC55C0Q37517465-7D88D0CC-FA45-4743-B1AD-D6472A02824AQ37893563-88F922E8-B6EB-4B23-9815-F44C90BE4032Q37902619-2D5C9414-1E48-49E5-A662-EA9471E8E833Q38110433-5C7C338B-AA10-42C7-9442-C2E694784EA1Q38120524-ECBA9AF5-7A0B-48E1-A77F-B3F16830AEEFQ38128342-A09F602B-AAC3-4CEE-9FCA-BF3E0E06ACF9Q38249204-E97BCCC2-1B07-4C79-AA5B-4B9006EC6381Q38264736-382CCBA0-4FD9-42DE-BC3E-09DDF5AF9B69Q38267138-901D88E8-6C46-4634-A256-BC1D83E7BBBDQ38442573-22827C90-2486-43E7-8199-4942210B7E5DQ38663214-EFC6B9E9-57DE-4FD5-BA2D-D66C4D66F225Q38990711-7B1CF3E3-30C0-4689-AB7D-A1DD9D8AD796Q39742032-C4108E64-3760-4F48-ACC6-DED9A1182734Q39816033-E57E1E69-8D73-4E92-9151-20231418FF01Q40505663-96CE492A-5C0C-4AD2-A3E8-AC8CDDD9D77FQ40890012-2CBA04FE-F85C-4408-AE40-488C34EBAF3CQ41592465-CCD7DBD8-DFCA-4151-84E7-500692A0742DQ41928814-707BE664-DD02-4EC7-9D6F-0AC3E0623AEDQ42199670-0B29EAD5-3F86-4D92-8551-263C80E270D8Q43405753-D0AF3476-50FC-4A52-B10A-CA75332DB6FBQ44869377-4D36D7C4-B1B8-4830-8ADA-DC61362300CBQ46383671-75A4FBC9-B0D6-499B-8CFE-C272DD94ACACQ53111655-782FE4C3-F119-4296-85D7-C9052F563255Q53224491-58343CF8-5C6D-4F0F-B709-42EA3F9AB0BBQ56984194-D0ECED7A-D88C-4188-AA54-5F8614AE682F
P2860
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@en
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@nl
type
label
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@en
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@nl
prefLabel
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@en
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@nl
P1476
Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.
@en
P2093
Jiunn H Lin
P304
P356
10.2174/138920009789895499
P407
P577
2009-09-01T00:00:00Z